Drug discovery

eBook: The orchestrated lab
#Automation #Automation / robotics #Drug discovery #eBook #Lab technology

The orchestrated lab: From automation to intelligent workflow management

Download this exclusive eBook from Thermo Fisher Scientific to learn more about: The global lab automation market and how it will develop in the next five years The benefits and limitations of automation use How the shift towards intelligent operational ecosystems is advancing drug discovery How scheduling software is enabling… Read More

#Resources

#AI #AstraZeneca #Drug discovery #Isomorphic Labs #Pistoia Alliance

From the Editor: The steady shift to AI

It is especially difficult within the life sciences sector – and indeed everyday life – to avoid mentions of AI and the inevitable changes it will bring, and is bringing, to drug discovery.   Further difficulty stems from the need to distinguish between hype, reality and fantasy. Drug discovery and development is a… Read More

#Exclusive Content

#AstraZeneca #Drug discovery #Life sciences #o2h #o2h Discovery #o2h Group #o2h Ventures

CWOW and the future of integrated drug discovery

Held from 11–19 June 2026, CWOW welcomed more than 5,000 attendees across 37 venues, delivering over 280 sessions and bringing together investors, entrepreneurs, academics, policymakers, operators, local communities and the wider biotech and techbio community from across the UK and beyond. Read more about the event here. Below, DDW speaks… Read More

#Exclusive Content

KRAS
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Webinar explores resistance to Pan-RAS(ON) inhibition

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News

#Bladder cancer #Covid-19 #Drug discovery #Heart disease #Lung disease #Oncology

This week in Drug Discovery (22-26 June) 

News round-up for 22–26 June by Bruno Quinney, Content Team at DDW.  This week, the Summer issue of DDW is now available to read. Elsewhere, researchers have uncovered clues explaining risks of heart disease, lung disease, Covid-19 and cancer.    The top stories: … Read More

#News

#AI #Autism #Drug design #Drug discovery #Immunotherapy #Neuroscience

Read the Summer issue of DDW

The latest issue of Drug Discovery World is out now. The DDW Summer 2026 issue examines the multi-compound approach to autism, the outlook for GLP-1 therapies and highlights drug discovery innovators and Investors – investment challenges and opportunities for drug developers. It also included features on: The importance of tech and collaboration for immunotherapies The… Read More

#News

#Drug discovery #Fragment-based drug discovery #Webinar

Webinar: Learn how to accelerate the early stages of drug discovery

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

#News

Lab automation
#Automation #Automation / robotics #Drug discovery #Lab technology #Webinar

Learn more about lab workflow scheduling and orchestration

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

#News

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

Watch now: Discover an NGS-based AVA assay with enhanced sensitivity and specificity

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. In this on-demand webinar, ViruSure, a global leader in pathogen safety testing, shares how it… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#News

Corporate collaboration
#Drug discovery #Merck

Protillion and Merck unveil drug discovery collaboration  

Protillion Biosciences has signed a drug discovery collaboration with Merck to “identify novel therapeutic candidates.”  The agreement combines Protillion’s proprietary platform, Prot-MaP, with Merck’s expertise in the discovery of novel therapeutic candidates.  The Prot-MaP technology is a megascale data generation platform, which Protillion says is purpose-built to deliver massive, just-in-time training sets to protein design… Read More

#News

Test for KRAS mutation
#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Lessons from 50+ patient-derived KRAS-mutant tumour models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

#News